CytomX Therapeutics Inc. (CTMX)
CytomX Therapeutics Statistics
Share Statistics
CytomX Therapeutics has 80.1M shares outstanding. The number of shares has increased by 2.8% in one year.
| Shares Outstanding | 80.1M |
| Shares Change (YoY) | 2.8% |
| Shares Change (QoQ) | 2.35% |
| Owned by Institutions (%) | 54.9% |
| Shares Floating | 78.13M |
| Failed to Deliver (FTD) Shares | 10.88K |
| FTD / Avg. Volume | 0.56% |
Short Selling Information
The latest short interest is 9.57M, so 11.95% of the outstanding shares have been sold short.
| Short Interest | 9.57M |
| Short % of Shares Out | 11.95% |
| Short % of Float | 12.03% |
| Short Ratio (days to cover) | 7.37 |
Valuation Ratios
The PE ratio is 2.73 and the forward PE ratio is -1.55. CytomX Therapeutics's PEG ratio is 0.
| PE Ratio | 2.73 |
| Forward PE | -1.55 |
| PS Ratio | 0.63 |
| Forward PS | 0.4 |
| PB Ratio | -190.73 |
| P/FCF Ratio | -1 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CytomX Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of -20.58.
| Current Ratio | 1.25 |
| Quick Ratio | 1.25 |
| Debt / Equity | -20.58 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | -0.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.16M |
| Profits Per Employee | $267.81K |
| Employee Count | 119 |
| Asset Turnover | 1.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 224K |
| Effective Tax Rate | 0.7% |
Stock Price Statistics
The stock price has increased by -83.11% in the last 52 weeks. The beta is 1.33, so CytomX Therapeutics's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -83.11% |
| 50-Day Moving Average | 0.64 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 60.17 |
| Average Volume (20 Days) | 1.93M |
Income Statement
In the last 12 months, CytomX Therapeutics had revenue of 138.1M and earned 31.87M in profits. Earnings per share was 0.38.
| Revenue | 138.1M |
| Gross Profit | 138.1M |
| Operating Income | 25M |
| Net Income | 31.87M |
| EBITDA | 25M |
| EBIT | 25M |
| Earnings Per Share (EPS) | 0.38 |
Balance Sheet
The company has 38.05M in cash and 9.38M in debt, giving a net cash position of 28.67M.
| Cash & Cash Equivalents | 38.05M |
| Total Debt | 9.38M |
| Net Cash | 28.67M |
| Retained Earnings | -691.58M |
| Total Assets | 120.53M |
| Working Capital | 21.53M |
Cash Flow
In the last 12 months, operating cash flow was -86.23M and capital expenditures -310K, giving a free cash flow of -86.54M.
| Operating Cash Flow | -86.23M |
| Capital Expenditures | -310K |
| Free Cash Flow | -86.54M |
| FCF Per Share | -1.02 |
Margins
Gross margin is 100%, with operating and profit margins of 18.1% and 23.08%.
| Gross Margin | 100% |
| Operating Margin | 18.1% |
| Pretax Margin | 23.24% |
| Profit Margin | 23.08% |
| EBITDA Margin | 18.1% |
| EBIT Margin | 18.1% |
| FCF Margin | -62.66% |
Dividends & Yields
CTMX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CTMX is $5.79, which is 661.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.79 |
| Price Target Difference | 661.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -5.71 |
| Piotroski F-Score | 6 |